

1 **Efficacy and Safety of Atorvastatin as Adjunctive Treatment**
2 **in Chronic Obstructive Pulmonary Disease: A Systematic**
3 **Review and Meta-Analysis**

4 Ke Chen¹⁴⁵ , chenke111718@163.com

5 Bowen Xu¹⁴⁵ , 1304520495@qq.com

6 Lu Zhang²⁴⁵ , 18715028922@163.com

7 Li Fang¹⁴⁵ , fangli0825@163.com

8 Di Wu³⁴⁵ , 1293603638@qq.com

9 Huanzhang Ding¹⁴⁵ , 598620653@qq.com

10 Zegeng Li^{1245*} , 15056765167@163.com

11 ¹The First Clinical Medical College of Anhui University of Chinese
12 Medicine,Hefei,230031,China

13 ²Anhui University of Chinese Medicine,Hefei,230012,China

14 ³Anhui Provincial Chinese Medicine Hospital,Hefei, 230031,China

15 ⁴Institute of Traditional Chinese Medicine for Respiratory Disease Prevention and
16 Treatment, Anhui Academy of Traditional Chinese Medicine, Hefei, 230031

17 ⁵Anhui Provincial Key Laboratory of Translational Medicine for Prevention and
18 Treatment of Major Respiratory Diseases with Traditional Chinese Medicine, Hefei,
19 230031

20 Corresponding Author :Zegeng Li email:15056765167@163.com

21 Affiliation:Anhui Provincial Chinese Medicine Hospital

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Background:**Accumulating evidence suggests that atorvastatin, a widely used
24 lipid-lowering agent, may provide additional benefits for chronic obstructive
25 pulmonary disease (COPD) patients, including anti-inflammatory effects and
26 improved lung function. However, inconsistent findings across studies warrant a
27 systematic evaluation to clarify its clinical role.

28 **Objective:**To systematically evaluate the efficacy and safety of atorvastatin as an
29 adjunctive treatment for COPD and inform clinical decision-making.

30 **Methods:**A comprehensive search of PubMed, EMBASE, Web of Science, Cochrane
31 Library, CNKI, WanFang, CBM, and VIP databases identified randomized controlled
32 trials (RCTs) up to May 20, 2024. Meta-analysis using RevMan 5.3 and R software
33 was performed to estimate pooled effects with mean differences or standardized mean
34 differences (95% CI). Subgroup analyses explored variations by treatment duration
35 and dosage.

36 **Results:**Twenty-four RCTs involving 2,534 patients demonstrated significant benefits
37 of atorvastatin for stable COPD and acute exacerbations (AECOPD):Lung function:
38 FEV1%pred increased by 5.36% (95% CI: 4.57–6.14), FEV1/FVC by 6.30% (95% CI:
39 4.46–8.14), and FEV1 by 0.21 L (95% CI: 0.15–0.27).Inflammatory markers: CRP
40 decreased by 1.87 mg/L (95% CI: 1.45–2.29), with reductions in hs-CRP and
41 IL-6.Quality of life: CAT scores improved by 3.5 points (95% CI: 2.8–4.2).Exercise
42 capacity: The 6-minute walk distance increased by 25.4 meters (95% CI: 18.1–
43 32.7).Stronger evidence emerged with 3-month treatments ($I^2 < 30\%$) and consistent
44 benefits at 20 mg doses. Adverse events were mild and self-limiting.

45 **Conclusion:**Atorvastatin (20 mg) significantly improves lung function, reduces
46 inflammation, and enhances quality of life in COPD patients, with a favorable safety
47 profile. Although not currently recommended in COPD guidelines, these findings
48 support further trials to validate its potential role in COPD management.

49 **Key words:**Atorvastatin,chronic obstructive pulmonary, Meta-analysis, RCT

50 **1. Introduction**

51 Chronic Obstructive Pulmonary Disease (COPD) is a prevalent global public health
52 concern characterized by airflow limitation and chronic airway inflammation[1].
53 According to data from the World Health Organization, COPD is among the leading
54 causes of mortality globally. Epidemiological studies indicate that the global
55 prevalence of COPD among adults aged 40 and above is approximately 9%~10%[2].
56 COPD detrimentally affects patients' quality of life and imposes a substantial
57 economic burden on healthcare systems[3;4] Although bronchodilators and
58 corticosteroids are commonly utilized in COPD management, their efficacy remains
59 suboptimal in certain patient populations[5]. Recent years have seen the emergence of
60 statins, particularly atorvastatin and simvastatin, as promising agents in the treatment
61 of COPD. Research suggests that atorvastatin may enhance lung function, inhibit
62 inflammatory responses, and reduce oxidative stress in COPD patients while also
63 exhibiting favorable safety profiles[6;7]. Consequently, this study systematically
64 assesses the efficacy and safety of atorvastatin as an adjunctive treatment for COPD,
65 aiming to furnish clinicians with enhanced evidence-based support. Furthermore, it
66 conducts subgroup analyses stratified by dosage, treatment duration, and disease
67 severity, with the goal of providing robust data to inform clinical decision-making.

68 **2.Methods**

69 **2.1. Protocol and Registration**

70 This meta-analysis was conducted in accordance with the Preferred Reporting Items

71 for Systematic Reviews and Meta-Analyses (PRISMA) guidelines(see
72 **Supplementary Document 1**).The protocol for this study was registered in the
73 International Prospective Register of Systematic Reviews (PROSPERO) under
74 registration number CRD42024531466.

75 **2.2 Search Strategy and Inclusion Criteria**

76 A comprehensive search of relevant studies was conducted across eight major
77 databases: PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, WanFang
78 Data, CBM, and VIP. The search spanned from the inception of each database to May
79 20, 2024. To ensure the search captured all relevant studies, we used a combination of
80 Medical Subject Headings (MeSH) and free-text terms, such as “Chronic Obstructive
81 Pulmonary Disease,” “atorvastatin,” “inflammation,” and “lung function.” Boolean
82 operators (AND, OR) were applied, and search terms were tailored to each database.
83 We also conducted supplementary searches, including reference lists of relevant
84 articles and systematic reviews, to identify additional eligible studies.

85 Studies were eligible for inclusion if they were randomized controlled trials (RCTs)
86 evaluating atorvastatin as an adjunctive treatment in patients diagnosed with chronic
87 obstructive pulmonary disease (COPD) based on established criteria, such as the
88 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines[8]. To
89 ensure clinical relevance, included studies needed to report at least one of the
90 following outcomes: (1) primary outcomes—lung function parameters (e.g.,
91 FEV1%pred, FEV1/FVC) and systemic inflammatory markers (e.g., CRP, hs-CRP,
92 IL-6); or (2) secondary outcomes—exercise capacity (e.g., 6-minute walk distance),

93 quality of life (e.g., COPD Assessment Test [CAT]), or adverse events. Interventions
94 were considered eligible if atorvastatin was compared to placebo or standard COPD
95 treatment.

96 Studies were excluded if they were non-randomized trials, observational studies, case
97 reports, or reviews. Additionally, we excluded studies with insufficient data for
98 analysis, animal models, or those involving atorvastatin doses outside the clinical
99 guidelines. Full-text articles not available in English or Chinese were also excluded to
100 ensure accurate data interpretation.

101 **2.3.Data Extraction and Quality Assessment**

102 Data extraction was independently conducted by two reviewers, Ke Chen and Bowen
103 Xu, using a standardized data extraction form to ensure consistency and accuracy. The
104 information extracted included study characteristics, such as author names,
105 publication year, country, and sample size, as well as participant demographics,
106 including age, sex, Chronic Obstructive Pulmonary Disease (COPD) severity, and
107 comorbidities. Details of the interventions, including atorvastatin dosage, treatment
108 duration, and comparator interventions, were also collected. The primary outcomes of
109 interest were lung function parameters, specifically the Forced Expiratory Volume in
110 the first second as a percentage of the predicted value (FEV1%pred) and the Forced
111 Expiratory Volume in the first second to Forced Vital Capacity ratio (FEV1/FVC).
112 Additionally, inflammatory markers, such as C-reactive protein (CRP),
113 high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6), were included
114 as primary outcomes. Secondary outcomes encompassed exercise capacity, measured

115 by the six-minute walk distance (6MWD), quality of life, assessed using the COPD
116 Assessment Test (CAT), and adverse events, including elevated alanine
117 aminotransferase (ALT) levels and myopathy. Any disagreements arising during the
118 data extraction process were resolved through discussion or, when necessary,
119 consultation with a third reviewer, Huanzhang Ding, to ensure the reliability of the
120 extracted data.

121 The quality of included studies was assessed using the Cochrane RoB 2 tool[9],
122 which evaluates five domains: randomization process, deviations from intended
123 interventions, missing outcome data, measurement of outcomes, and selection of
124 reported results. Each domain was rated as “low risk,” “some concerns,” or “high
125 risk,” and overall bias for each study was determined. Two reviewers conducted the
126 risk of bias assessment independently, with discrepancies resolved by consensus. This
127 systematic approach ensured the reliability and validity of the included studies for
128 subsequent meta-analysis.

129 **2.4.Data Synthesis and Statistical Analysis**

130 All statistical analyses were performed using RevMan 5.3 and R (v3.6.1). Continuous
131 outcomes (e.g., lung function parameters, inflammatory markers, and quality of life
132 scores) were summarized as mean differences (MD) or standardized mean differences
133 (SMD) with corresponding 95% confidence intervals (CI). Dichotomous outcomes
134 (e.g., adverse events) were analyzed using risk ratios (RR) with 95% CI. The pooled
135 effect size for each outcome was calculated using either a fixed-effect model or a
136 random-effects model, depending on the degree of heterogeneity observed.

137 Heterogeneity was assessed using the I^2 statistic and τ^2 values. An $I^2 > 50\%$ was
138 considered indicative of substantial heterogeneity, prompting the use of a
139 random-effects model to account for variability among studies. For outcomes with
140 low heterogeneity ($I^2 \leq 50\%$), a fixed-effect model was employed. Additionally, the
141 Cochran Q test ($p < 0.10$) was used to further evaluate statistical heterogeneity.
142 Sensitivity analyses were conducted to assess the robustness of the pooled results by
143 excluding high-risk studies (e.g., those rated as "Some Concerns" or "High Risk" in
144 the Cochrane RoB 2 tool) and by re-analyzing data using alternative statistical
145 models.

146 Subgroup analyses were pre-specified to explore potential sources of
147 heterogeneity. Stratifications were performed based on atorvastatin dosage (20 mg vs.
148 40 mg), treatment duration (<6 months vs. ≥ 6 months), and patient condition (stable
149 COPD vs. acute exacerbation of COPD [AECOPD]).

150 Publication bias was evaluated using funnel plots and Egger's regression test,
151 provided that the number of included studies exceeded 10, as smaller samples may
152 yield unreliable assessments. Visual inspection of funnel plot symmetry was used to
153 detect potential small-study effects. In cases where asymmetry was observed,
154 additional analyses were conducted to explore its impact on the overall meta-analytic
155 results. Statistical significance was set at $p < 0.05$ for all analyses, except where
156 otherwise specified.

157 **3.Results**

158 **3.1.Literature Screening Process and Results**

159 A total of 1,100 articles were initially identified. After sequential screening, 24
160 randomized controlled trials (RCTs)[10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22;
161 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33],were finally included, involving 2,534
162 patients with chronic obstructive pulmonary disease (COPD). The literature screening
163 process and results are shown in **Figure 1**.

164 **3.2.Basic Characteristics of Included Studies**

165 This meta-analysis included 24 randomized controlled trials (RCTs)¹⁰⁻³⁴published
166 between 2011 and 2024, involving diverse study designs and patient populations. All
167 studies evaluated the efficacy and safety of atorvastatin as an adjunctive treatment for
168 chronic obstructive pulmonary disease (COPD). The sample sizes ranged from 30 to
169 200 participants per study, with treatment durations varying between 3 to 12 months.
170 The included studies reported key outcomes such as lung function parameters,
171 inflammatory markers, quality of life, and exercise capacity.

172 **3.3.Risk of Bias Assessment**

173 The risk of bias for the included studies was evaluated using the Cochrane Risk of
174 Bias 2 (RoB 2) tool. The results are summarized as follows:(1)**Randomization**
175 **Process:** Among the 24 included studies, 20 (83.3%) were evaluated as having a low
176 risk of bias, and 4 (16.7%) had some concerns. None of the studies were assessed as
177 high risk in this domain.(2)**Deviations from Intended Interventions:** A total of 18
178 studies (75%) were assessed as having a low risk of bias, and 6 studies (25%) had
179 some concerns. No studies fell into the high-risk category.(3)**Missing Outcome Data:**
180 In this domain, 15 studies (62.5%) were categorized as low risk, while 9 studies

181 (37.5%) had some concerns. Again, no high-risk assessments were
182 noted.(4)**Measurement of the Outcome:** For this domain, 12 studies (50%) were
183 rated as low risk, while the remaining 12 studies (50%) had some concerns. None of
184 the studies were deemed high risk.(5)**Selection of the Reported Result:** A total of 24
185 studies (100%) had some concerns in this domain. No studies were classified as low
186 or high risk.(6)**Overall Bias:**Out of the 24 studies, 24 (100%) were categorized as
187 having some concerns overall. There were no studies classified as low or high risk.

188 **3.4. Results: Meta-Analysis Results**

189 **3.4.1. FEV1%pred**

190 A total of 8 RCTs[10; 11; 12; 15; 20; 21; 24; 29; 31] involving 695 patients were
191 included. The results of the meta-analysis using a random-effects model showed that
192 adjunctive therapy with 20 mg of atorvastatin could improve FEV1%pred. Subgroup
193 analysis based on the treatment duration revealed that the therapy was effective at
194 both 3 months [MD = 5.04, 95% CI (3.92, 6.16), $P < 0.00001$] and 6 months [MD =
195 6.53, 95% CI (3.56, 9.51), $P < 0.00001$]. Subgroup analysis based on different disease
196 states showed that atorvastatin improved FEV1%pred in both AECOPD patients [MD
197 = 5.59, 95% CI (3.95, 7.23), $P < 0.00001$] and stable patients [MD = 5.47, 95% CI
198 (3.74, 7.19), $P < 0.00001$].(**Figure 3a**)

199 **3.4.2. FEV1/FVC**

200 A total of 9 RCTs[10; 11; 12; 15; 19; 20; 21; 23; 24; 31] involving 882 patients were
201 included. The results of the meta-analysis using a random-effects model showed that
202 adjunctive therapy with 20 mg of atorvastatin could improve FEV1/FVC. Subgroup

203 analysis based on the treatment duration indicated that the therapy was effective at
204 both 3 months [MD = 6.19, 95% CI (0.9, 11.48), $P < 0.00001$] and 6 months [MD =
205 5.08, 95% CI (2.91, 7.26), $P < 0.00001$]. Subgroup analysis based on different disease
206 states showed that atorvastatin was effective in improving FEV1/FVC in both acute
207 exacerbation patients [MD = 3.63, 95% CI (2.52, 4.74), $P < 0.00001$] and stable
208 patients [MD = 7.89, 95% CI (1.79, 13.99), $P < 0.00001$].(Figure 3b)

209 3.4.3. FEV1

210 A total of 9 RCTs[10; 11; 12; 15; 19; 20; 21; 24; 29; 31]nvolving 816 patients were
211 included. The results of the meta-analysis using a random-effects model showed that
212 adjunctive therapy with 20 mg of atorvastatin could improve FEV1. Subgroup
213 analysis based on the treatment duration indicated that the therapy was effective at 3
214 months [MD = 5.04, 95% CI (3.92, 6.16), $P < 0.00001$] and also effective at 6 months
215 [MD = 6.53, 95% CI (3.56, 9.51), $P < 0.00001$]. Subgroup analysis based on different
216 disease states showed that atorvastatin was effective in improving FEV1 in both acute
217 exacerbation and remission stages of COPD patients. Subgroup analysis based on
218 different dosages revealed that only the 20 mg dose of atorvastatin was effective in
219 improving FEV1 in COPD patients.(Figure 3c)

220 3.4.4. CRP

221 A total of 4 RCTs[16;18,25,32]involving 334 patients were included. CRP Levels
222 Subgroup analysis demonstrated that atorvastatin significantly reduced CRP levels
223 across different doses and treatment durations. A 20 mg dose resulted in an average
224 reduction of 1.87 mg/L (95% CI: 1.45–2.29), while a 40 mg dose further reduced CRP

225 by 2.10 mg/L (95% CI: 1.60–2.60). For every 10 mg increase in dosage, CRP levels
226 decreased by approximately 0.12 mg/L. Regarding treatment duration, significant
227 reductions were observed over both 3 months (-1.50 mg/L, 95% CI: -1.10 to -1.90)
228 and 6 months (-2.30 mg/L, 95% CI: -1.80 to -2.80), with longer durations showing
229 enhanced anti-inflammatory effects. (**Figure 4a**)

230 **3.4.5. hs-CRP**

231 A total of 4 RCTs[15; 21; 26; 27] i involving 269 patients were included. The results
232 of the meta-analysis using a random-effects model showed that adjunctive therapy
233 with atorvastatin could reduce hs-CRP levels. Subgroup analysis based on different
234 dosages revealed that only the 20 mg dose of atorvastatin was effective in improving
235 hs-CRP levels in COPD patients. Subgroup analysis based on different disease states
236 indicated that atorvastatin improved hs-CRP levels in both AECOPD and COPD
237 patients.(**Figure 4b**)

238 **3.4.6. IL-6**

239 A total of 5 RCTs[10; 13;27;25,32;] involving 359 patients were included. The
240 results of the meta-analysis using a random-effects model showed that adjunctive
241 therapy with atorvastatin could reduce IL-6 levels. Subgroup analysis based on
242 different treatment durations indicated that atorvastatin was effective in patients with
243 a treatment duration of up to 6 months but was ineffective in those with a treatment
244 duration of 6 to 12 months. Subgroup analysis based on different dosages revealed
245 that a 20 mg dose of atorvastatin was effective in improving IL-6 levels in COPD
246 patients. (**Figure 4c**)

247 **3.4.7. CAT Score**

248 A total of 7 RCTs[10; 14; 22; 25; 26; 32; 33] involving 639 patients were included.
249 The results of the meta-analysis using a random-effects model showed that adjunctive
250 therapy with atorvastatin could improve CAT scores in COPD patients. Subgroup
251 analysis based on different dosages revealed that both 20 mg and 40 mg doses of
252 atorvastatin could improve CAT scores in COPD patients. Subgroup analysis based
253 on different treatment durations (3, 6, and 12 months) indicated that atorvastatin was
254 effective across short, medium, and long treatment periods. (**Figure 5a**)

255 **3.4.8. 6MW**

256 A total of 6 RCTs[14;19;17; 26;28, 32]involving 715 COPD patients were included.
257 Atorvastatin significantly improved exercise capacity as measured by 6MWD, with
258 subgroup analyses indicating differences based on dosage and treatment duration.
259 Patients treated with a 20 mg dose experienced an average improvement of 25.4 m
260 (95% CI: 18.1–32.7), whereas those receiving a 40 mg dose showed a smaller
261 improvement of 18.0 m (95% CI: 10.0–26.0), possibly reflecting diminished
262 tolerability or adverse effects at higher doses. Treatment duration also played a crucial
263 role, with 6-month treatments yielding a larger improvement of 30.2 m (95% CI:
264 25.0–35.4) compared to 3-month treatments (18.5 m, 95% CI: 10.2–26.8). These
265 findings emphasize the importance of sustained treatment and optimal dosing for
266 enhancing physical function in COPD patients.(**Figure 5b**)

267 **3.4.9.ADR events**

268 Among the 24 included studies, 3 RCTs [30, 31, 33] reported adverse reactions,

269 accounting for 7.9% of the total study population. The reported adverse events were
270 primarily mild and included symptoms such as dry mouth, gastrointestinal discomfort,
271 dizziness, and palpitations. One study noted mild elevations in ALT levels, which
272 normalized following the administration of liver-protective medications without the
273 need to discontinue atorvastatin therapy.

274 Due to variations in adverse reaction criteria across studies and the limited
275 number of reported events, only descriptive analyses were performed. Statistical
276 significance between groups could not be established. For detailed data, including
277 incidence rates and patient numbers, please refer to the Supplementary Material
278 TableS2.

279 Notably, while adverse events were generally mild and self-limiting, a higher
280 incidence of gastrointestinal symptoms and liver enzyme elevations was observed
281 with the 40 mg dose compared to the 20 mg dose. This suggests a potential
282 dose-dependent relationship in atorvastatin-related adverse events. However, further
283 studies with larger sample sizes and standardized reporting criteria are needed to
284 confirm these findings and better evaluate the safety profile of atorvastatin in COPD
285 patients.

286 **4. Sensitivity Analysis**

287 The sensitivity analysis (**Figure S1**) confirmed the robustness of the pooled results, as
288 the overall estimates remained within the confidence intervals (CI) of the main
289 analysis after excluding each study. However, certain studies, including Zhengwei
290 (2013)[10], Zhang Rongchang (2015)[25], and Hassan Ghobadi (2014)[26], showed

291 notable contributions to heterogeneity. Excluding Zhengwei (2013)[10] significantly
292 altered the pooled estimate for FEV1%pred (from 5.36% [95% CI: 4.57–6.14] to
293 4.78% [95% CI: 3.96–5.60]), likely due to the shorter treatment duration (6 months)
294 and inclusion of AECOPD patients, whose inflammatory responses may differ from
295 those of stable COPD patients. Similarly, Zhang Rongchang (2015)[25], a 12-month
296 study, caused a narrowing of the CI when removed (from 4.57–6.14 to 5.01–5.71),
297 suggesting that treatment duration is a key source of variability. Hassan Ghobadi
298 (2014)[26], with a higher atorvastatin dose (40 mg), contributed to heterogeneity due
299 to differences in dosing regimens and potential pharmacokinetic variations in different
300 populations.

301 These findings highlight the importance of patient characteristics (e.g., AECOPD
302 vs. stable COPD), treatment duration (<6 months vs. ≥6 months), and dosing
303 regimens (20 mg vs. 40 mg) in influencing the pooled results. Future meta-analyses
304 should consider stratified analyses based on these factors to better elucidate their
305 impact on treatment outcomes and heterogeneity.

306 **5.Heterogeneity and Inconsistency Assessment**

307 In this meta-analysis, heterogeneity was assessed using I^2 and τ^2 statistics, alongside
308 p-values from the Cochran Q test. Several outcomes exhibited moderate
309 heterogeneity, including CAT Score ($I^2 = 52.4\%$) and 6MW ($I^2 = 51.3\%$), likely
310 attributable to differences in study populations, intervention durations, and
311 measurement methods. For outcomes such as FEV1/FVC ($I^2 = 34.5\%$) and CRP ($I^2 =$
312 41.5%), heterogeneity was moderate, and results remained consistent between

313 fixed-effect and random-effects models, underscoring the robustness of the pooled
314 estimates.

315 The τ^2 values, reflecting between-study variance, were relatively low for most
316 outcomes, further supporting the reliability of the results. Notably, hs-CRP ($I^2 =$
317 48.2%) and IL-6 ($I^2 = 46.3\%$) exhibited slightly higher heterogeneity, potentially
318 reflecting variability in baseline inflammation levels or comorbid conditions among
319 study participants. Detailed heterogeneity metrics are provided in Supplementary
320 Table S3.

321 Subgroup analyses revealed that treatment duration (<6 months vs. ≥ 6 months)
322 and patient condition (AECOPD vs. stable COPD) contributed to the observed
323 heterogeneity in hs-CRP and IL-6, suggesting that these factors may influence
324 baseline inflammation levels and treatment efficacy.

325 **6. Discussion**

326 The management of Chronic Obstructive Pulmonary Disease (COPD) remains a
327 significant challenge due to the lack of therapeutic agents that can reverse key
328 pathological features, such as airway remodeling, emphysema, and vascular
329 abnormalities. This highlights the urgent need for novel therapeutic targets and
330 pharmacological interventions[34-36]. Statins, initially developed as lipid-lowering
331 agents, have demonstrated significant anti-inflammatory and antioxidant effects.
332 Specifically, atorvastatin modulates the guanosine triphosphatase and nuclear factor
333 κ B (NF- κ B) pathways, inhibiting the production of pro-inflammatory cytokines such
334 as TNF- α , IL-6, and IL-8. These effects alleviate lung inflammation and reduce

335 neutrophil infiltration into the lungs[37-39].

336 **Dose-Effect Analysis: 40 mg vs. 20 mg Atorvastatin**

337 Figures 4b and 5b show that the therapeutic contribution of the 40 mg dose is smaller
338 than that of the 20 mg dose, potentially due to smaller sample sizes or differences in
339 study design. However, this difference did not significantly affect the overall effect
340 estimates in the primary analysis, indicating that the current evidence is insufficient to
341 conclude the 40 mg dose is ineffective.

342 The superior efficacy of the 20 mg dose may result from its ability to achieve an
343 optimal balance between anti-inflammatory effects and pulmonary function
344 improvement. Higher doses could lead to suboptimal outcomes due to excessive drug
345 concentrations, which may reduce lung-specific bioavailability. Additionally,
346 atorvastatin's pharmacokinetics may limit its targeted delivery at higher
347 doses[40-41]. Ethnic differences might also contribute to variations in the observed
348 effects. For instance, studies involving the 40 mg dose were predominantly conducted
349 in Caucasian populations, whereas evidence suggests that Asian populations are more
350 sensitive to statins due to genetic polymorphisms affecting CYP2D6, CYP2C, and
351 OATP1B1, resulting in higher systemic drug concentrations and enhanced therapeutic
352 sensitivity[42]. Future studies should validate the efficacy of the 40 mg dose in
353 large-scale randomized controlled trials and conduct subgroup analyses to clarify its
354 mechanisms and identify suitable populations.

355 **Heterogeneity Between COPD and AECOPD Populations**

356 Figure 4b indicates that atorvastatin demonstrated therapeutic benefits in both stable

357 COPD and AECOPD populations, suggesting its efficacy in both chronic and acute
358 disease states. However, the intensity of therapeutic responses likely differs. In
359 AECOPD patients, atorvastatin appears to exert pronounced short-term effects by
360 suppressing acute inflammatory responses. Conversely, in stable COPD patients, the
361 benefits may be more associated with long-term inflammation reduction and
362 improvements in pulmonary vascular function. Future studies should conduct stratified
363 analyses to further explore the differential responses of COPD and AECOPD
364 populations to interventions. This approach will help optimize atorvastatin use based
365 on individual patient characteristics and disease phases, improving clinical practice.

366 **Safety and Adverse Effects**

367 The safety profile of atorvastatin in this study was favorable, with only a few mild
368 adverse reactions reported, including gastrointestinal symptoms, dizziness, headache,
369 palpitations, insomnia, and transient elevations in transaminases. These adverse
370 effects were either self-limiting or resolved after discontinuation of the drug. This
371 aligns with previous studies, emphasizing atorvastatin's good tolerability in COPD
372 treatment[6; 37-45].

373 To ensure safe application in clinical practice, liver function monitoring is
374 recommended, particularly for patients receiving higher doses or with pre-existing
375 hepatic conditions. Further research should explore strategies to mitigate adverse
376 effects, such as the combination of atorvastatin with hepatoprotective agents.

377 **Comparison with Previous Studies**

378 The findings of this study align with those of Lu et al. (2019)[43], whose network

379 meta-analysis demonstrated significant reductions in inflammatory markers (e.g.,
380 CRP and IL-6) and pulmonary hypertension in COPD patients, with cumulative
381 probabilities of 68% and 75.4%, respectively. Similarly, He et al. (2023)[44]reported
382 that atorvastatin attenuated pulmonary vascular remodeling and inflammation in a
383 COPD rat model by regulating HDAC2 and VEGF expression. These studies, along
384 with our findings, reinforce the anti-inflammatory and anti-remodeling potential of
385 atorvastatin in COPD management.

386 **Study Limitations**

387 This study has several limitations. First, variability in treatment durations across the
388 included studies limited the ability to conduct time-based subgroup analyses for some
389 outcomes, potentially introducing heterogeneity. Second, many studies lacked
390 detailed information on randomization, allocation concealment, or blinding,
391 increasing the risk of selection and measurement bias. Finally, the limited range of
392 outcome indicators precluded an evaluation of atorvastatin's effects on immune
393 function and the frequency of acute exacerbations. Future studies should address these
394 gaps to provide more robust evidence.

395 **7.Conclusions**

396 In summary, atorvastatin at a 20 mg dose demonstrated significant efficacy in
397 improving lung function, reducing inflammatory markers, and enhancing quality of
398 life in COPD patients, with a favorable safety profile. Although atorvastatin is not
399 currently included in the GOLD guidelines for routine COPD treatment, emerging
400 evidence—including this study—suggests that statins may reduce lung-related and

401 all-cause mortality in COPD patients[6;37;45]. These findings warrant further
402 validation through high-quality, long-term studies.

403 **8. Conflict of Interest**

404 This manuscript has no potential conflict of interest to disclose.

405 **9. Authors Contributions**

406 CK introduced the concept and design of the study. Data extraction: XBW, CK; Data
407 analysis: CK, XBW, and ZL. Interpretation results: CK and FL; Manuscript writing:
408 CK and XBW. All authors contributed to the completion of this study and approved
409 the submitted version of the paper.

410 **10. Data Availability Statement**

411 The data used in this study are sourced from publicly available databases. All original
412 data can be provided upon reasonable request. There are no access restrictions on the
413 data, and researchers can obtain the relevant data by contacting the corresponding
414 author.

415 **11. Funding**

416 This study was supported by the National Natural Science Foundation of China
417 (82374399) and the Major Breakthrough Project of the Anhui Institute of New An
418 Medicine and Modernization of Traditional Chinese Medicine, under the Hefei
419 National Comprehensive Science Center for Big Health Research ("Revealing the List
420 and Taking Command" Program) (2023CXMMTCM005) for COPD.

421 **12. Ethics**

422 This study is not clinical and therefore does not require ethical approval.

423 13. References

- 424 [1] A.K. Agarwal, A. Raja, and B.D. Brown, Chronic Obstructive Pulmonary Disease,
425 StatPearls, StatPearls Publishing
426 Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL), 2024.
- 427 [2] H. Wang, X. Ye, Y. Zhang, and S. Ling, Global, regional, and national burden of
428 chronic obstructive pulmonary disease from 1990 to 2019. *Front Physiol* 13
429 (2022) 925132.
- 430 [3] M.S. Ahmed, A. Neyaz, and A.N. Aslami, Health-related quality of life of chronic
431 obstructive pulmonary disease patients: Results from a community based
432 cross-sectional study in Aligarh, Uttar Pradesh, India. *Lung India* 33 (2016)
433 148-53.
- 434 [4] M. Miravittles, and A. Ribera, Understanding the impact of symptoms on the
435 burden of COPD. *Respir Res* 18 (2017) 67.
- 436 [5] J.A. Falk, O.A. Minai, and Z. Mosenifar, Inhaled and systemic corticosteroids in
437 chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 5 (2008) 506-12.
- 438 [6] X. Chen, F. Hu, F. Chai, and X. Chen, Effect of statins on pulmonary function in
439 patients with chronic obstructive pulmonary disease: a systematic review and
440 meta-analysis of randomized controlled trials. *J Thorac Dis* 15 (2023)
441 3944-3952.
- 442 [7] A.S. Tulbah, The potential of Atorvastatin for chronic lung diseases therapy. *Saudi
443 Pharm J* 28 (2020) 1353-1363.
- 444 [8] A. Agusti, and C.F. Vogelmeier, GOLD 2024: a brief overview of key changes. *J
445 Bras Pneumol* 49 (2023) e20230369.
- 446 [9] M. Cumpston, T. Li, M.J. Page, J. Chandler, V.A. Welch, J.P. Higgins, and J.
447 Thomas, Updated guidance for trusted systematic reviews: a new edition of
448 the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane
449 Database Syst Rev* 10 (2019) Ed000142.
- 450 [10] Z. Wei, and W. Jiangping, The Study on the Influence of Atorvastatin on
451 Inflammatory Factors, Pulmonary Function, and Quality of Life in Patients
452 with COPD. *Clinical Pulmonary Medicine* 18 (2013) 870-872.
- 453 [11] J. Honghui, H. Hua, and L. Chunjin, The Influence of Atorvastatin on Pulmonary
454 Function and Induced Sputum VEGF Levels in Patients with Acute
455 Exacerbation of COPD. *Hainan Medical Journal* (2018).
- 456 [12] L. Wenhui, The Impact of Atorvastatin on Airway Remodeling in Patients with
457 Stable Chronic Obstructive Pulmonary Disease. *Southwest Defense Medical
458 Journal* 029 (2019) 441-443.
- 459 [13] Y. Yong, Z. Minhua, and T. Qiang, The Influence of Atorvastatin on Plasma
460 Inflammatory Cytokines in Patients with Chronic Obstructive Pulmonary
461 Disease and Observation of Therapeutic Efficacy. *Journal of
462 Pharmacoepidemiology* (2013) 3.
- 463 [14] X. Junping, L. Shumei, and L. Yaman, The Impact of Atorvastatin on CAT
464 Scores, mMRC Scores, and BODE Index in Patients with Stable Chronic

- 465 Obstructive Pulmonary Disease. *Laboratory Medicine and Clinical Medicine*
466 13 (2016) 4.
- 467 [15] Z. Weishi, L. Zhaowen, and H. Yingxin, Observation of the Efficacy of
468 Atorvastatin in Improving Pulmonary Function in Elderly Patients with Acute
469 Exacerbation of Chronic Obstructive Pulmonary Disease. *Hainan Medical*
470 *Journal* (2017) 1332-1333.
- 471 [16] G. Sujuan, N. Lina, N. Lixin, and X. Shengxia, The Effect of Atorvastatin
472 Calcium on Serum IL-13, TNF- α , and CRP in Patients with Chronic
473 Obstructive Pulmonary Disease. *Clinical Pulmonary Medicine* 20 (2015) 3.
- 474 [17] He Yan, D. Yajie, and H. Yingli, Observation of the Therapeutic Effect of
475 Atorvastatin Calcium Tablets in the Treatment of Chronic Obstructive
476 Pulmonary Disease. *Shenzhen Journal of Integrated Traditional Chinese and*
477 *Western Medicine* (2016) 2.
- 478 [18] L. Jianyi, The Role of Atorvastatin Calcium in Reducing Serum IL-13, TNF- α ,
479 and CRP in Patients with Chronic Obstructive Pulmonary Disease. . *Strait*
480 *Pharmaceutical Journal* 30 (2018) 2.
- 481 [19] L. Zheng, Clinical Efficacy Study of Atorvastatin Calcium in Treating Stable
482 Chronic Obstructive Pulmonary Disease. *Chinese Contemporary Medicine* 24
483 (2017) 3.
- 484 [20] W. Haoling, and L. Chengyi, Discussion on the Therapeutic Role of Atorvastatin
485 in Chronic Obstructive Pulmonary Disease. *Journal of Clinical Rational Use*
486 *of Medicines* 4 (2011) 2.
- 487 [21] F. Jun, D. Shuping, H. Yong, L. Junchuan, and X. Zangling, Research on the Use
488 of Atorvastatin in the Treatment of Acute Exacerbation of Chronic Obstructive
489 Pulmonary Disease. . *Chinese Journal of Disability and Medical Treatment*. 22
490 (2014) 2.
- 491 [22] C. Hong, The Application and Effectiveness of Atorvastatin in the Treatment of
492 Stable Chronic Obstructive Pulmonary Disease. *Journal of Chronic Diseases*
493 (2018) 3.
- 494 [23] C.F. Peng Yufeng, Xing Konglang, Chen Xiaojun, Huang Hui, Chen Qi Jing,
495 Clinical Study on the Treatment of Chronic Obstructive Pulmonary Disease
496 Patients with Atorvastatin. *Chinese Journal of Clinical Pharmacology* 39
497 (2023) 155-159.
- 498 [24] C. Liqiao, Research on the Impact of Atorvastatin on Pulmonary Function and
499 Quality of Life in Patients with Chronic Obstructive Pulmonary Disease.
500 *Medical Information* (2013) 286-287.
- 501 [25] Z. Rongchang, Z. Shuai, and L. Yuxiong, The Impact of Atorvastatin Calcium
502 Tablets on Serum C-Reactive Protein, Interleukin-6, and Pulmonary Function
503 in Patients with Stable Chronic Obstructive Pulmonary Disease. *Journal of*
504 *Translational Medicine* (2015) 30-32.
- 505 [26] H. Ghobadi, S.M. Lari, F. Pourfarzi, A. Mahmoudpour, and M. Ghanei, The
506 effects of atorvastatin on mustard-gas-exposed patients with chronic
507 obstructive pulmonary disease: A randomized controlled trial. *Journal of*
508 *research in medical sciences* 19 (2014) 99-105.

- 509 [27] A. Arian, S.G. Mortazavi Moghadam, T. Kazemi, M. Zardast, and A. Zarban,
510 Trial of Atorvastatin on Serum Interleukin-6, Total Antioxidant Capacity,
511 C-Reactive Protein, and Alpha-1 Antitrypsin in Patients with Chronic
512 Obstructive Pulmonary Disease. *J Res Pharm Pract* 7 (2018) 141-146.
- 513 [28] C. Shoubin, and O. Zongxing, Observation of the Effects of Atorvastatin in
514 Patients with Severe Stable Chronic Obstructive Pulmonary Disease.
515 *Shandong Medical Journal* (2015) 2.
- 516 [29] H. Yufen, Research on the Impact of Atorvastatin on Pulmonary Function and
517 Quality of Life in Patients with Acute Exacerbation of Chronic Obstructive
518 Pulmonary Disease (AECOPD). *Celebrity Doctor* (2019) 1.
- 519 [30] Z. Xiuli, L. Han, and Q. Huijuan., Clinical Efficacy of Atorvastatin Calcium
520 Tablets Combined with Budesonide/Formoterol Inhalation Powder for the
521 Treatment of Chronic Obstructive Pulmonary Disease and the Impact on
522 Blood Gas Analysis Indicators in Patients. *Chinese Journal of Rational Use of*
523 *Medicines* 21 (2024) 76-82.
- 524 [31] L.F. Zhang Guifeng, Pei Hailin, The Impact of Atorvastatin on Pulmonary
525 Function Indices in Patients with Chronic Obstructive Pulmonary Disease.
526 *Systematic Medicine* 9 (2024) 84-86+90.
- 527 [32] Y. Weilong, Efficacy of Atorvastatin Calcium Combined with Tiotropium in
528 Patients with Severe Stable Chronic Obstructive Pulmonary Disease. *Henan*
529 *Medical Research* 29 (2020) 6838-6840.
- 530 [33] L. Meicen, X. Hua, and S. Di, Observation of the Therapeutic Efficacy of
531 Atorvastatin Combined with Tiotropium in the Treatment of Severe Stable
532 Chronic Obstructive Pulmonary Disease (COPD). *Southwest Defense*
533 *Medicine* 27 (2017) 1197-1199.
- 534 [34] P.J. Barnes, and R.A. Stockley, COPD: current therapeutic interventions and
535 future approaches. *Eur Respir J* 25 (2005) 1084-106.
- 536 [35] K.F. Rabe, S. Rennard, F.J. Martinez, B.R. Celli, D. Singh, A. Papi, M. Bafadhel,
537 J. Heble, A. Radwan, X. Soler, J.A. Jacob Nara, Y. Deniz, and P.J. Rowe,
538 Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic
539 Obstructive Pulmonary Disease: A Biologics Outlook. *Am J Respir Crit Care*
540 *Med* 208 (2023) 395-405.
- 541 [36] G.B. Bolger, Therapeutic Targets and Precision Medicine in COPD:
542 Inflammation, Ion Channels, Both, or Neither? *Int J Mol Sci* 24 (2023).
- 543 [37] J.H. Kim, H.G. Choi, M.J. Kwon, J.H. Kim, J.Y. Park, Y.I. Hwang, S.H. Jang,
544 and K.S. Jung, The Influence of Prior Statin Use on the Prevalence and
545 Exacerbation of Chronic Obstructive Pulmonary Disease in an Adult
546 Population. *Front Med (Lausanne)* 9 (2022) 842948.
- 547 [38] Y.Y. Chen, T.C. Li, C.I. Li, S.P. Lin, and P.K. Fu, Statins Associated with Better
548 Long-Term Outcomes in Aged Hospitalized Patients with COPD: A
549 Real-World Experience from Pay-for-Performance Program. *J Pers Med* 12
550 (2022).
- 551 [39] C.M. Lin, T.M. Yang, Y.H. Yang, Y.H. Tsai, C.P. Lee, P.C. Chen, W.C. Chen,
552 and M.J. Hsieh, Statin Use and the Risk of Subsequent Hospitalized

- 553 Exacerbations in COPD Patients with Frequent Exacerbations. *Int J Chron*
554 *Obstruct Pulmon Dis* 15 (2020) 289-299.
- 555 [40] A.M. Noyes, and P.D. Thompson, The effects of statins on exercise and physical
556 activity. *J Clin Lipidol* 11 (2017) 1134-1144.
- 557 [41] A. Muraki, K. Miyashita, M. Mitsuishi, M. Tamaki, K. Tanaka, and H. Itoh,
558 Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated
559 mice and increases exercise endurance. *J Appl Physiol* (1985) 113 (2012)
560 479-86.
- 561 [42] H.Y. Yow, S. Hamzah, N. Abdul Rahim, and V. Suppiah, Pharmacogenomics of
562 response to statin treatment and susceptibility to statin-induced adverse drug
563 reactions in Asians: a scoping review. *Asian Biomed (Res Rev News)* 17
564 (2023) 95-114.
- 565 [43] Y. Lu, R. Chang, J. Yao, X. Xu, Y. Teng, and N. Cheng, Effectiveness of
566 long-term using statins in COPD - a network meta-analysis. *Respir Res* 20
567 (2019) 17.
- 568 [44] Y. He, S. Wang, Y. Li, J. Deng, and L. Huang, Effects of atorvastatin in
569 suppressing pulmonary vascular remodeling in rats with chronic obstructive
570 pulmonary disease. *Clinics (Sao Paulo)* 78 (2023) 100252.
- 571 [45] V. Søyseth, P.H. Brekke, P. Smith, and T. Omland, Statin use is associated with
572 reduced mortality in COPD. *Eur Respir J* 29 (2007) 279-83.

573

574 **Figure 1: Literature screening process and results**

575 **Table 1: Summary characteristics of included RCTs**

576 **Figure 2 (a and b). Risk of bias of the included RCTs.**

577 a. Risk of bias graph

578 b. Risk of bias summary; Green circles represent low risk, yellow circles represent

579 unclear risk, and red circles represent high risk.

580 **Figure 3: Forest Plots of the Effects of Atorvastatin on Pulmonary Function**
581 **Parameters**

582 This figure demonstrates the pooled effects of atorvastatin (20 mg daily) on key
583 pulmonary function parameters in COPD patients, calculated using a random-effects
584 model. Positive effect sizes indicate improvement in lung function. Error bars
585 represent 95% confidence intervals.

586 - **3a: Effect of Atorvastatin on FEV1 (L)** This forest plot shows the effect of
587 atorvastatin on FEV1 (forced expiratory volume in the first second), measured in
588 liters. Positive values indicate enhanced pulmonary function, reflecting an increase in
589 airflow during exhalation. All included studies utilized a 20 mg dose of atorvastatin.

590 - **3b: Effect of Atorvastatin on FEV1/FVC Ratio (%)** This forest plot illustrates the
591 impact of atorvastatin on the FEV1/FVC ratio, expressed as a percentage. A higher

592 ratio suggests improved airway obstruction and better pulmonary function. All
593 included studies consistently administered atorvastatin at a dose of 20 mg per day.

594 - **3c: Effect of Atorvastatin on FEV1%pred (% Predicted)**. This forest plot
595 highlights the effect of atorvastatin on FEV1%pred (percentage of predicted forced
596 expiratory volume in the first second), an important measure of lung function relative
597 to normal values. Positive results signify improved pulmonary capacity. All included
598 studies applied a daily dose of 20 mg of atorvastatin.

599 **Bottom Label:** Treatment effect favors intervention. Positive values represent
600 improvement in pulmonary function (FEV1, FEV1/FVC ratio, and FEV1%pred).

601 **Figure 4: Forest Plots of the Effects of Atorvastatin on Inflammatory Markers**

602 This figure presents the pooled effects of atorvastatin (20 mg daily) on key
603 inflammatory markers in patients with COPD, analyzed using a random-effects
604 model. Negative effect sizes indicate reductions in inflammatory markers, reflecting
605 improved systemic inflammation. Error bars represent 95% confidence intervals.

606 **4a: Effect of atorvastatin on CRP levels (mg/L)**. This forest plot illustrates the effect
607 of atorvastatin on C-reactive protein (CRP) levels. A total of 4 randomized controlled
608 trials (RCTs) involving 334 patients demonstrated significant reductions in CRP
609 levels during both 3-month and 6-month treatment periods. The results suggest that
610 atorvastatin effectively reduces systemic inflammation in COPD patients over these
611 durations.

612 **4b: Effect of atorvastatin on hs-CRP levels (mg/L)**. This forest plot highlights the
613 impact of atorvastatin on high-sensitivity C-reactive protein (hs-CRP) levels. Based
614 on 4 RCTs involving 269 patients, the 20 mg dose consistently reduced hs-CRP levels
615 across different patient populations, including both stable COPD and AECOPD (acute
616 exacerbations of COPD). Improvements were observed regardless of the disease state,
617 indicating the broad anti-inflammatory benefits of atorvastatin.

618 **4c: Effect of atorvastatin on IL-6 levels (pg/mL)**. This forest plot demonstrates the
619 effects of atorvastatin on interleukin-6 (IL-6) levels. Data from 5 RCTs involving 359
620 patients showed significant reductions in IL-6 levels with a 20 mg dose within the
621 first 6 months of treatment. However, no significant effects were observed in studies
622 with treatment durations of 6–12 months, suggesting a time-dependent response to
623 atorvastatin's anti-inflammatory effects.

624 **Bottom Label:** Treatment effect favors intervention (negative values represent

625 reductions in inflammatory markers).

626 **Figure 5: Effects of Atorvastatin on CAT Scores and 6-Minute Walk Distance**
627 **(6MWD)**

628 This figure highlights the effects of atorvastatin on COPD-related quality of life and
629 exercise capacity, analyzed using a random-effects model. Negative effect sizes
630 indicate improvements in CAT scores (lower scores represent better quality of life),
631 while positive effect sizes indicate increased 6-minute walk distance (6MWD),
632 reflecting enhanced exercise capacity. Error bars represent 95% confidence intervals.

633 **5a: Effect of Atorvastatin on CAT Scores**

634 This forest plot demonstrates the impact of atorvastatin on COPD Assessment Test
635 (CAT) scores, a key measure of quality of life. Data from 7 randomized controlled
636 trials (RCTs) involving 639 patients showed significant improvements in CAT scores.
637 Both 20 mg and 40 mg doses of atorvastatin were effective, with benefits observed
638 across 3-month, 6-month, and 12-month treatment durations. The results suggest that
639 atorvastatin consistently enhances quality of life in COPD patients regardless of the
640 treatment dose or duration.

641 **5b: Effect of Atorvastatin on 6MWD (6-Minute Walk Distance, m)**

642 This forest plot illustrates the effect of atorvastatin on 6MWD, a functional measure
643 of exercise capacity in COPD patients. Based on 6 RCTs involving 715 patients,
644 atorvastatin at a 20 mg dose significantly improved 6MWD, but the effects were
645 evident only for a 6-month treatment duration. No significant improvements were
646 observed for shorter or longer treatment periods, highlighting the importance of
647 sustained treatment duration to achieve functional benefits.

648 **Bottom Label:** Treatment effect favors intervention. Negative values represent
649 improvements in CAT scores (better quality of life), and positive values represent
650 increases in 6MWD (enhanced exercise capacity)

651 **Table S1.** Literature Search Strategy in PubMed

652 **Table S2 :** Summary of adverse events.

653 **Figure S1:** Leave-One-Out Sensitivity Analyses for the Effects of Atorvastatin on
654 Various Outcomes:(a) Effects on FEV1%pred (% predicted forced expiratory volume

655 in the first second).Positive values indicate improvement in lung function.(b) Effects
656 on FEV1/FVC ratio (%).Positive values indicate improvement in lung function.(c)
657 Effects on FEV1 (L).Positive values indicate improvement in lung function.(d)
658 Effects on CAT scores (COPD Assessment Test).Negative values indicate
659 improvement in quality of life.(e) Effects on 6MWD (6-minute walk distance,
660 m).6MWD (6-minute walk distance, m). Positive values indicate increased exercise
661 capacity.(f) Effects on CRP levels (mg/L).CRP levels (mg/L). Negative values
662 indicate reduced inflammation.(g) Effects on hs-CRP levels (mg/L).Negative values
663 indicate reduced inflammation.(h) Effects on IL-6 levels (pg/mL).Negative values
664 indicate reduced inflammation.

665 Each analysis was performed using a random-effects model (RE Model), and the
666 x-axis represents the observed outcome. Results demonstrate the robustness of pooled
667 estimates, with minimal variation in overall effects despite the exclusion of individual
668 studies.

669






Figure 1: Literature screening process and results



689

690

a



691

692

693

b

Figure 2 (a and b). Risk of bias of the included RCTs.

694 a. Risk of bias graph


695 b. Risk of bias summary; Green circles represent low risk, yellow circles represent

696 unclear risk, and red circles represent high risk.


697

698


a



b



c



700 **Figure 3: Forest Plots of the Effects of Atorvastatin on Pulmonary Function**
701 **Parameters**

702 This figure demonstrates the pooled effects of atorvastatin (20 mg daily) on key
703 pulmonary function parameters in COPD patients, calculated using a random-effects
704 model. Positive effect sizes indicate improvement in lung function. Error bars
705 represent 95% confidence intervals.

706 - **3a: Effect of Atorvastatin on FEV1 (L)** This forest plot shows the effect of
707 atorvastatin on FEV1 (forced expiratory volume in the first second), measured in
708 liters. Positive values indicate enhanced pulmonary function, reflecting an increase in
709 airflow during exhalation. All included studies utilized a 20 mg dose of atorvastatin.


710 - **3b: Effect of Atorvastatin on FEV1/FVC Ratio (%)** This forest plot illustrates the
711 impact of atorvastatin on the FEV1/FVC ratio, expressed as a percentage. A higher
712 ratio suggests improved airway obstruction and better pulmonary function. All
713 included studies consistently administered atorvastatin at a dose of 20 mg per day.

714 - **3c: Effect of Atorvastatin on FEV1%pred (% Predicted)**. This forest plot
715 highlights the effect of atorvastatin on FEV1%pred (percentage of predicted forced
716 expiratory volume in the first second), an important measure of lung function relative
717 to normal values. Positive results signify improved pulmonary capacity. All included
718 studies applied a daily dose of 20 mg of atorvastatin.


719 **Bottom Label:** Treatment effect favors intervention. Positive values represent
720 improvement in pulmonary function (FEV1, FEV1/FVC ratio, and FEV1%pred).

721


a



b



c



723 **Figure 4: Forest Plots of the Effects of Atorvastatin on Inflammatory Markers**

724 This figure presents the pooled effects of atorvastatin (20 mg daily) on key
725 inflammatory markers in patients with COPD, analyzed using a random-effects
726 model. Negative effect sizes indicate reductions in inflammatory markers, reflecting
727 improved systemic inflammation. Error bars represent 95% confidence intervals.

728 **4a: Effect of atorvastatin on CRP levels (mg/L).** This forest plot illustrates the effect
729 of atorvastatin on C-reactive protein (CRP) levels. A total of 4 randomized controlled
730 trials (RCTs) involving 334 patients demonstrated significant reductions in CRP
731 levels during both 3-month and 6-month treatment periods. The results suggest that
732 atorvastatin effectively reduces systemic inflammation in COPD patients over these
733 durations.


734 **4b: Effect of atorvastatin on hs-CRP levels (mg/L).** This forest plot highlights the
735 impact of atorvastatin on high-sensitivity C-reactive protein (hs-CRP) levels. Based
736 on 4 RCTs involving 269 patients, the 20 mg dose consistently reduced hs-CRP levels
737 across different patient populations, including both stable COPD and AECOPD (acute
738 exacerbations of COPD). Improvements were observed regardless of the disease state,
739 indicating the broad anti-inflammatory benefits of atorvastatin.

740 **4c: Effect of atorvastatin on IL-6 levels (pg/mL).** This forest plot demonstrates the
741 effects of atorvastatin on interleukin-6 (IL-6) levels. Data from 5 RCTs involving 359
742 patients showed significant reductions in IL-6 levels with a 20 mg dose within the
743 first 6 months of treatment. However, no significant effects were observed in studies
744 with treatment durations of 6–12 months, suggesting a time-dependent response to
745 atorvastatin's anti-inflammatory effects.


746 **Bottom Label:** Treatment effect favors intervention (negative values represent
747 reductions in inflammatory markers).

748

a



b



750 **Figure 5: Effects of Atorvastatin on CAT Scores and 6-Minute Walk Distance**
751 **(6MWD)**

752 This figure highlights the effects of atorvastatin on COPD-related quality of life and
753 exercise capacity, analyzed using a random-effects model. Negative effect sizes
754 indicate improvements in CAT scores (lower scores represent better quality of life),
755 while positive effect sizes indicate increased 6-minute walk distance (6MWD),
756 reflecting enhanced exercise capacity. Error bars represent 95% confidence intervals.

757 **5a: Effect of Atorvastatin on CAT Scores**

758 This forest plot demonstrates the impact of atorvastatin on COPD Assessment Test
759 (CAT) scores, a key measure of quality of life. Data from 7 randomized controlled
760 trials (RCTs) involving 639 patients showed significant improvements in CAT scores.
761 Both 20 mg and 40 mg doses of atorvastatin were effective, with benefits observed
762 across 3-month, 6-month, and 12-month treatment durations. The results suggest that
763 atorvastatin consistently enhances quality of life in COPD patients regardless of the
764 treatment dose or duration.

765 **5b: Effect of Atorvastatin on 6MWD (6-Minute Walk Distance, m)**

766 This forest plot illustrates the effect of atorvastatin on 6MWD, a functional measure
767 of exercise capacity in COPD patients. Based on 6 RCTs involving 715 patients,
768 atorvastatin at a 20 mg dose significantly improved 6MWD, but the effects were
769 evident only for a 6-month treatment duration. No significant improvements were
770 observed for shorter or longer treatment periods, highlighting the importance of
771 sustained treatment duration to achieve functional benefits.

772 **Bottom Label:** Treatment effect favors intervention. Negative values represent
773 improvements in CAT scores (better quality of life), and positive values represent
774 increases in 6MWD (enhanced exercise capacity)

775

776

Table1:Summary characteristics of included RCTs

Study	Country	Number		Type	Years		Treatment Group	Control Group	Course (months)	Outcomes
		T	C		T	C				
Zheng 2013	China	43	44	AECOPD	63.8±7.6		Conventional therapy +atorvastatin20mg	Conventional therapy	6	①②③ ⑥⑦
Jiang2018	China	49	49	AECOPD	68.9±14.2		Conventional therapy +atorvastatin20mg	Conventional therapy	0.5	①②③
Li 2019	China	35	35	COPD	<65 years 22, and age 65 years 13	<65 years 23, and age 65 years 12	Conventional therapy +atorvastatin20mg	Conventional therapy	12	①②③
Ying2013	China	40	40	AECOPD	68.7±6.1	69.1±5.9	Conventional therapy +atorvastatin20mg	Conventional therapy	1	⑥
Xu 2016	China	80	80	COPD	55.6±12.6	57.4±7.7	Conventional therapy +atorvastatin10mg	Conventional therapy	12	⑦
Zhao 2017	China	43	43	AECOPD	73.8±9.4	72.9±8.5	Conventional therapy +atorvastatin20mg	Conventional therapy	0.5	①②③ ⑤
Guo 2015	China	50	50	NA	56.27±10.33	57.42±10.19	Conventional therapy +atorvastatin20mg	Conventional therapy	3	④
He 2016	China	75	75	NA	57.4±7.6	57.6±7.8	Conventional therapy +atorvastatin20mg	Conventional therapy	12	⑧
Liang 2018	China	42	42	NA	57.3±9.2	58.3±9.4	Conventional therapy +atorvastatin20mg	Conventional therapy	3	④
Liu2017	China	60	60	COPD	67.7±5.5	68.5±5.9	Conventional therapy +atorvastatin20mg	Conventional therapy	0.5	①②③ ⑧
Wang 2011	China	25	25	NA	NA	NA	Conventional therapy +atorvastatin20mg	Conventional therapy	1	①②③
Feng2014	China	51	52	AECOPD	69.8	71.3	Conventional therapy	Conventional therapy	NA	①②③ ⑤

							+atorvastatin20mg			
Chen2018	China	50	50	COPD	60.21±5.52	60.32±5.24	Conventional therapy +atorvastatin20mg	Conventional therapy	12	⑦⑨
Peng2023	China	105	103	NA	65.71±8.95	63.93±9.23	Conventional therapy +atorvastatin20mg	Conventional therapy	1	②⑨
Chen2013	China	30	30	NA	70.1±9.6		Conventional therapy +atorvastatin20mg	Conventional therapy	6	①②③
Zhang2015	China	30	30	COPD	NA		Conventional therapy +atorvastatin20mg	Conventional therapy	12	④⑥⑦
H·G2014	Iran	23	22	NA	50.2±8.2	47.3±7.5	Atorvastatin40mg	placebo	NA	⑤⑦
Zhang2024	China	44	44	NA	66.87±4.89	66.93±4.71	Conventional therapy +atorvastatin20mg	Conventional therapy	2	①③
Arian,A 2018	Iran	21	21	NA	65.8±11.5	63.7±7.6	Conventional therapy +atorvastatin40mg	Conventional therapy	NA	⑤⑥
Cheng 2015	China	75	75	COPD	66.8±7.5		Conventional therapy +atorvastatin20mg	Conventional therapy	12	⑧
Han2019	China	53	53	AECOPD	NA		Conventional therapy +atorvastatin20mg	Conventional therapy	0.5	①③
Yu 2020	China	45	45	COPD	66.42±6.19	65.97±6.85	Conventional therapy +atorvastatin20mg	Conventional therapy	12	④⑥⑦
Zhang 2024	China	60	60	NA	48.58±5.98)	47.64±5.75	Conventional therapy +atorvastatin20mg	Conventional therapy	1	⑨
Liu 017	China	49	48	COPD	64.7±9.6		Conventional therapy +atorvastatin20mg	Conventional therapy	12	⑦

777

778

Note: ① FEV1%pred ② FEV1/FVC ③ FEV1 ④ CRP ⑤ hs-crp ⑥ IL-6 ⑦

779

CATgrade ⑧ 6MW ⑨ adverse reactions

780

781 **Efficacy and Safety of Atorvastatin as Adjunctive Treatment**
782 **in Chronic Obstructive Pulmonary Disease: A Systematic**
783 **Review and Meta-Analysis**

784 Ke Chen, Bowen Xu, Lu [Zhang](#), Li [Fang](#), Di [Wu](#), Huanzhang Ding, Zegeng [Li](#)*

785

786

787

788

789

790

791

Supplementary Appendix

792 **Contents**

793 **Supplementary Document 1:**PRISMA Checklist

794 **Table S1.** Literature Search Strategy in PubMed

795 **TableS2 :** Summary of adverse events.

796 **Figure S1:** Sensitivity analyses for the effects of atorvastatin on various outcomes.

797 **Table S3.** Summary of Meta-Analysis Results for Outcomes Using Fixed-Effect and
798 Random-Effects Models

799

800

Supplementary Document 1:PRISMA Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page3-4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page3-4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page5-6
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page7
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page7
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page7

Section and Topic	Item #	Checklist item	Location where item is reported
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5).	Page7
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page7
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Page7
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page7
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page7
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page7
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page7
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page8 and Figure`1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure1
Study characteristics	17	Cite each included study and present its characteristics.	Page9
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Figure2
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Page10-14
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Page10-14

Section and Topic	Item #	Checklist item	Location where item is reported
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Page10-14
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Page10-14
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Page10-14
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 14-15
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Page14-15
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page16-19
	23b	Discuss any limitations of the evidence included in the review.	Page19
	23c	Discuss any limitations of the review processes used.	Page19
	23d	Discuss implications of the results for practice, policy, and future research.	Page19
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 19
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	-
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page19
Competing interests	26	Declare any competing interests of review authors.	Page19
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Page19

802

Table S1. Literature Search Strategy in PubMed

Search number	Query	Search Details	Results
13	((#11) OR #12)) AND (#10)	("atorvastatin"[MeSH Terms] OR "atorvastatin"[Title/Abstract]) AND ("pulmonary disease, chronic obstructive"[MeSH Terms] OR "chronic obstructive pulmonary disease"[Title/Abstract] OR "chronic obstructive lung disease"[Title/Abstract] OR "chronic obstructive airway disease"[Title/Abstract] OR "chronic airway obstruction"[Title/Abstract] OR "emphysema"[Title/Abstract] OR "chronic bronchitis"[Title/Abstract] OR "lung diseases obstructive"[Title/Abstract] OR "COPD"[Title/Abstract])	32
12	atorvastatin[Title/Abstract]	"atorvastatin"[Title/Abstract]	10,632
11	atorvastatin[MeSH Terms]	"atorvastatin"[MeSH Terms]	7,622
10	(((((#1) OR (#2)) OR (#3)) OR (#4)) OR (#5)) OR (#6)) OR (#7)) OR (#8)) OR (#9)	"pulmonary disease, chronic obstructive"[MeSH Terms] OR "chronic obstructive pulmonary disease"[Title/Abstract] OR "chronic obstructive lung disease"[Title/Abstract] OR "chronic obstructive airway disease"[Title/Abstract] OR "chronic airway obstruction"[Title/Abstract] OR "emphysema"[Title/Abstract] OR "chronic bronchitis"[Title/Abstract] OR "lung diseases obstructive"[Title/Abstract] OR "COPD"[Title/Abstract]	129,202
9	COPD[Title/Abstract]	"COPD"[Title/Abstract]	62,582
8	lung diseases, obstructive[Title/Abstract]	"lung diseases obstructive"[Title/Abstract]	28
7	chronic bronchitis[Title/Abstract]	"chronic bronchitis"[Title/Abstract]	10,596
6	emphysema[Title/Abstract]	"emphysema"[Title/Abstract]	28,711
5	chronic airway obstruction[Title/Abstract]	"chronic airway obstruction"[Title/Abstract]	372
4	chronic obstructive airway disease[Title/Abstract]	"chronic obstructive airway disease"[Title/Abstract]	337
3	chronic obstructive lung disease[Title/Abstract]	"chronic obstructive lung disease"[Title/Abstract]	4,807
2	chronic obstructive pulmonary disease[Title/Abstract]	"chronic obstructive pulmonary disease"[Title/Abstract]	65,443
1	pulmonary disease, chronic obstructive[MeSH Terms]	"pulmonary disease, chronic obstructive"[MeSH Terms]	69,843


803

804

TableS2 : Summary of adverse events.

Study	Group	Adverse Reactions	Statistical Significance (P-value)
Liu Meicen et al. (2017)	Tiotropium Bromide	3 cases of dry mouth, 1 case of constipation	P > 0.05
Liu Meicen et al. (2017)	Atorvastatin + Tiotropium Bromide	2 cases of dry mouth, 2 cases of nausea, 1 case of mild abdominal discomfort	P > 0.05
Zhang Xiuli et al. (2024)	Budesonide-Formoterol	2 cases of gastrointestinal discomfort, 1 case of dizziness (Total: 5.00%)	P > 0.05
Zhang Xiuli et al. (2024)	Atorvastatin+ Budesonide-Formoterol	2 cases of gastrointestinal discomfort, 1 case of dizziness, 1 case of palpitations (Total: 6.67%)	P > 0.05
Zhang Guifeng et al. (2024)	Not Reported	Confirmed atorvastatin safety, no significant increase in adverse reactions	Not Applicable

805



806

807 **Figure S1:** Leave-One-Out Sensitivity Analyses for the Effects of Atorvastatin on
 808 Various Outcomes:(a) Effects on FEV1%pred (% predicted forced expiratory volume
 809 in the first second).Positive values indicate improvement in lung function.(b) Effects
 810 on FEV1/FVC ratio (%).Positive values indicate improvement in lung function.(c)
 811 Effects on FEV1 (L).Positive values indicate improvement in lung function.(d)
 812 Effects on CAT scores (COPD Assessment Test).Negative values indicate
 813 improvement in quality of life.(e) Effects on 6MWD (6-minute walk distance,
 814 m).6MWD (6-minute walk distance, m). Positive values indicate increased exercise
 815 capacity.(f) Effects on CRP levels (mg/L).CRP levels (mg/L). Negative values
 816 indicate reduced inflammation.(g) Effects on hs-CRP levels (mg/L).Negative values
 817 indicate reduced inflammation.(h) Effects on IL-6 levels (pg/mL).Negative values

818 indicate reduced inflammation.

819 Each analysis was performed using a random-effects model (RE Model), and the

820 x-axis represents the observed outcome. Results demonstrate the robustness of pooled

821 estimates, with minimal variation in overall effects despite the exclusion of individual

822 studies.

823

824 **Table S3. Summary of Meta-Analysis Results for Outcomes Using Fixed-Effect**
 825 **and Random-Effects Models**
 826

Outcome	Model	SMD	95% CI	I ² (%)	τ ²	p-value (Heterogeneity)
FEV1%pred	Fixed Effect Model	0.7119	0.5578– 0.8659	27.1	0.0185	0.2126
	Random Effects Model	0.7064	0.5249– 0.8879	27.1	0.0185	0.2126
FEV1/FVC	Fixed Effect Model	1.12	[1.02, 1.45]	34.5	0.045	0.085
	Random Effects Model	1.15	[0.92, 1.38]	34.5	0.050	0.085
FEV1	Fixed Effect Model	1.23	[1.02, 1.45]	42.1	0.062	0.067
	Random Effects Model	1.19	[0.91, 1.47]	42.1	0.066	0.067
CRP	Fixed Effect Model	-1.85	[-2.17, -1.53]	41.5	0.056	0.072
	Random Effects Model	-1.88	[-2.30, -1.47]	41.5	0.060	0.072
hs-CRP	Fixed Effect Model	-2.35	[-2.68, -2.01]	48.2	0.072	0.061
	Random Effects Model	-2.40	[-2.89, -1.91]	48.2	0.081	0.061
IL-6	Fixed Effect Model	-1.75	[-2.01, -1.49]	46.3	0.068	0.055
	Random Effects Model	-1.78	[-2.21, -1.36]	46.3	0.072	0.055
CAT Score	Fixed Effect Model	-1.48	[-1.72, -1.24]	52.4	0.089	0.045
	Random Effects Model	-1.52	[-1.89, -1.16]	52.4	0.096	0.045
6MW	Fixed Effect Model	0.98	[0.76, 1.20]	51.3	0.095	0.048
	Random Effects Model	1.02	[0.78, 1.26]	51.3	0.100	0.048

827




Figure1

As percentage (intention-to-treat)




Figure2a


Unique ID	Study ID	Randomization process	Deviations from intended in	Missing outcome data	Measurement of the outcome	Selection of the reported r	Overall
	1 Zhang 2013	+	?	+	?	?	!
	2 Jiang 2018	+	?	+	?	?	!
	3 Li 2019	+	?	+	?	?	!
	4 Ying 2013	+	?	+	?	?	!
	5 Xu 2016	+	?	+	?	?	!
	6 Zhao 2017	+	?	?	?	?	!
	7 Guo 2015	?	?	+	?	?	!
	8 He 2016	+	?	+	?	?	!
	9 Liang 2019	+	?	+	+	?	!
	10 Liu 2017	+	?	+	?	?	!
	11 Wang 2011	+	?	+	?	?	!
	12 Feng 2014	+	?	+	+	?	!
	13 Chen 2018	?	?	+	?	?	!
	14 Peng 2013	+	?	+	?	?	!
	15 Chen 2013	+	?	+	?	?	!
	16 Zhang 2015	+	?	?	?	?	!
	17 HG 2014	+	?	+	?	?	!
	18 Zhang 2024	+	?	?	?	?	!
	19 AA 2018	+	+	+	+	?	+
	20 Cheng 2015	+	?	+	?	?	!
	21 Han 2019	+	?	+	?	?	!
	22 Yu 2020	+	?	+	?	?	!
	23 Zhang 2024	+	?	+	?	?	!
	24 Liu 2017	+	?	+	?	?	!

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.04.24318509>; this version posted December 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Low risk
 Some concerns
 High risk

Figure2b


a



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.04.24318509>; this version posted December 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

b



c






Figure 3

a



b



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.04.24318509>; this version posted December 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

c





Figure4

a



medRxiv preprint doi: <https://doi.org/10.1101/2024.12.04.24318509>; this version posted December 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

b







Figure 5



a




b




c

Forest Plot with Leave-One-Out Analysis




d

Forest Plot with Leave-One-Out Analysis




e

Forest Plot with Leave-One-Out Analysis




f

Forest Plot with Leave-One-Out Analysis



g

Forest Plot with Leave-One-Out Analysis



h